Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Merger Talks May Herald Next Step In Consumer-Focused Rx Marketing

Executive Summary

Procter & Gamble's aborted merger discussions with Warner-Lambert and American Home Products may herald the next phase in the evolution of consumer-focused pharmaceutical marketing.

You may also be interested in...



Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13

Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13

P&G Actonel Payment Postponed: $50 Mil. Delay Contributes To $40 Bil. Drop

The delay in the approval of Procter & Gamble's Actonel for osteoporosis contributed to the company's $38.7 bil. drop in value following the March 7 announcement that it will miss its earnings targets.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel